Quick Summary
Ikra 50mg Tablet
Last updated on 11 Sep 2026 | 05:33 AM (IST)
₹1874
MRP: ₹2285
(You Save ₹411)
4 TABLET(s) IN A STRIP
18% OFF
₹1874
MRP: ₹2,285.00
Inclusive of all taxes
18% Off
Dispatch: Today
Care delivered without the wait. Your order is prioritized for rapid dispatch to ensure it reaches your doorstep on time.
Substitutes
Claxven 50mg Tablet
LUCIEN LIFE SCI...
₹ 585.71/tablet
26% costlier
Venclexta 50mg Tablet
ABBVIE THERAPEU...
₹ 1695.00/tablet
262% costlier
Introduction
Ikra 50mg Tablet contains the active ingredient Venetoclax. Ikra 50mg Tablet is an antineoplastic drug that belongs to the class of BCL-2 inhibitors. It is used to treat adults with certain types of blood cancers, including chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML).
Specifically, it is used in CLL with a 17p deletion and in AML in patients who cannot undergo intensive chemotherapy. Additionally, it can be used in combination with other medications to treat certain types of non-Hodgkin lymphoma.
Ikra 50mg Tablet works by inhibiting the BCL-2 protein, which helps promote cancer cell death. This action restores the process of apoptosis (programmed cell death) by binding to BCL-2, displacing pro-apoptotic proteins, and initiating mitochondrial outer membrane permeabilisation, which triggers cell death.
Do not take Ikra 50mg Tablet if you are allergic to Venetoclax or any of the other ingredients in the medication. Before starting treatment, inform your doctor if you have kidney problems, a history of infections, or any blood-related disorders like low white blood cell count or low platelet count.
Ensure that your physician is aware of any past history of Tumour Lysis Syndrome (TLS) or if you are pregnant or planning to become pregnant, as Venclexta may harm the fetus. Ikra 50mg Tablet should not be used in children or adolescents under the age of 18.
Uses
Ikra 50mg Tablet is used in the treatment of the following:
Chronic lymphocytic leukaemia (CLL), including CLL with 17p deletion
Acute myeloid leukaemia (AML) in adults who cannot undergo intensive chemotherapy
Certain types of non-Hodgkin lymphoma, when combined with other medications
How Ikra 50mg Tablet works
Ikra 50mg Tablet works as a selective, orally bioavailable small-molecule inhibitor of BCL-2, an antiapoptotic protein. In CLL and AML cells, BCL-2 overexpression supports tumour cell survival and chemotherapy resistance by binding directly to BCL-2. Ikra 50mg Tablet displaces pro-apoptotic proteins like BIM, triggering mitochondrial outer membrane permeabilisation and activating caspases. Nonclinical studies demonstrate venetoclax’s cytotoxic effect on tumour cells overexpressing BCL-2.
Interaction of Valentax 100 mg with other drugs
It is important to inform your healthcare professional about all the medications you are taking, including prescription drugs, over-the-counter medications, nutritional supplements, and herbal products. Some medications may interact with Ikra 50mg Tablet, potentially affecting its effectiveness or causing side effects.
Storage
Keep out of reach of children and pets.
Store Ikra 50mg Tablet in the original packaging to protect from moisture.
Avoid direct sunlight
Store Ikra 50mg Tablet at a temperature not exceeding 30°C.
How to take Ikra 50mg Tablet
Ikra 50mg Tablet is administered orally. Do not break, chew, or crush the tablets. Follow the prescribed dosing schedule and consult your healthcare provider to determine the correct dosage. If you miss a dose, do not double the dose. Contact your healthcare provider for guidance.
Safety Advice
Pregnancy
It is unsafe to consume Ikra 50mg Tablet during pregnancy, as it may cause harm to the fetus when administered to pregnant women.
Breast Feeding
It is unknown if Ikra 50mg Tablets are safe to take during breastfeeding. Please consult your healthcare provider if you have any concerns.
Lungs
If you have any pre-existing lung conditions, discuss them with your doctor before starting treatment with Ikra 50mg Tablet.
Liver
If you have any pre-existing lung conditions, discuss them with your doctor before starting treatment with Ikra 50mg Tablet.
Alcohol
It is unknown whether alcohol consumption is safe while you are undergoing a Ikra 50mg Tablet course. It is recommended to consult your doctor for better guidance.
Driving
Ikra 50mg Tablet has no or negligible influence on the ability to drive and use machines, so it is generally safe to use.
Side Effects
Side effects are unwanted symptoms caused by medicines. Although all drugs can cause side effects, not everyone experiences them.
Common side effects of Ikra 50mg Tablet are
Fatigue
Anemia
Nausea
Diarrhea
Low platelet count (thrombocytopenia)
Low white blood cell count (neutropenia)
Serious side effects of Ikra 50mg Tablet are:
Risk of death
Tumour lysis syndrome (TLS)
Kidney failure
Need for dialysis treatment
Expert Tips
Ikra 50mg Tablet can cause serious side effects like Tumour Lysis Syndrome (TLS), neutropenia, and infections, requiring close monitoring and prophylactic treatment, especially during the ramp-up phase. It may also harm the fetus, so women of reproductive potential should avoid pregnancy during treatment. Regular blood counts are essential to detect neutropenia, and live attenuated vaccines should be avoided. Follow your healthcare provider’s instructions carefully, stay hydrated, and notify your doctor immediately if you experience symptoms like fever or unusual tiredness.
FAQs
Q1.
What is the new cancer drug Ikra 50mg Tablet?
Ikra 50mg Tablet is a cancer drug used to treat certain blood cancers, including chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML). It works by inhibiting the BCL-2 protein, which helps cancer cells survive, promoting their death.
Q2.
What type of chemo is Ikra 50mg Tablet?
Ikra 50mg Tablet is not a traditional chemotherapy drug. It is a targeted therapy that inhibits the BCL-2 protein to promote the death of cancer cells.
Q3.
How successful is Ikra 50mg Tablet?
Ikra 50mg Tablet has shown significant success in treating chronic lymphocytic leukaemia (CLL) and acute myeloid leukaemia (AML), especially in patients with high-risk forms of these cancers. Clinical studies demonstrate improved survival rates and remission in many patients.
Q4.
Does Ikra 50mg Tablet lower platelets?
Yes, Ikra 50mg Tablet can lower platelet counts, leading to thrombocytopenia in some patients. Regular blood tests are needed to monitor platelet levels during treatment.
Q5.
Does Ikra 50mg Tablet cause side effects?
Yes, Ikra 50mg Tablet can cause side effects. Common ones include nausea, diarrhoea, fatigue, and low blood cell counts. It can also lead to more serious effects, such as tumour lysis syndrome (TLS) and infections. Regular monitoring by a healthcare provider is essential to manage and prevent complications.
Fact Box
Molecule name | Venetoclax |
Therapeutic class | Antineoplastic agent |
Pharmacological class | BCL-2 inhibitor |
Indications | 1. Chronic lymphocytic leukaemia (CLL), including CLL with 17p deletion 2. Acute myeloid leukaemia (AML) in adults unable to undergo intensive chemotherapy 3. Certain non-Hodgkin lymphoma types, in combination with other medications |
References
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208573s013lbl.pdf
2. Juárez-Salcedo LM, Desai V, Dalia S. Venetoclax: evidence to date and clinical potential. Drugs Context. https://pmc.ncbi.nlm.nih.gov/articles/PMC6788387/
3. Waggoner M, Katsetos J, Thomas E, Galinsky I, Fox H. Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukaemia and Acute Myeloid Leukaemia. https://pmc.ncbi.nlm.nih.gov/articles/PMC9214960/
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
Did you find this information helpful?
Author Details
Written By
Dr Arathy J S
BDS
Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 11 Sep 2026 | 05:33 AM (IST)
Want to know more?
Read Our Editorial Policy
